Relmada Therapeutics, Inc. RLMD · Stock Open Relmada Therapeutics, Inc. in new tab
Relmada Therapeutics, Inc. Analysis (RLMD)
Is Relmada Therapeutics, Inc. a good investment? Relmada Therapeutics, Inc. (RLMD) is currently trading at 5.30 USD. Market analysts have a consensus price target of 12.67 USD. This suggests a potential upside from current levels.
Earnings Schedule: Relmada Therapeutics, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.41.
Investor FAQ
Does Relmada Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Relmada Therapeutics, Inc.?
Relmada Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.09.
Company Profile
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 12, 2015 | 0.200000 |
| Sept. 30, 2019 | 0.250000 |
Community Discussion